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Pitt-Hopkins syndrome (PTHS) is a severe neurodevelopmental disorder characterized by 
developmental delay, hyperactivity, seizures, lack of speech, and high autism comorbidity. 
Unfortunately, it has no known cure. The pathogenic mechanism in PTHS is decreased protein 
level of Transcription Factor 4 (TCF4) due to a mutation or deletion in one copy of TCF4. TCF4 
is a basic Helix-Loop-Helix (bHLH) transcription factor that regulates hundreds of genes. 
Consequently, it is nearly impossible to therapeutically address the full phenotypic spectrum of 
the disorder by targeting downstream molecular pathways. Ideally, PTHS can be treated by 
normalizing the expression of TCF4, but this strategy has not yet been tested. We took advantage 
of a mouse model of PTHS (called Tcf4LGSL/+), designed to restore TCF4 expression with 
temporal precision. We found that reinstating TCF4 expression during embryonic development 
can restore wild type behavioral phenotypes. However, reinstating TCF4 expression during 
postnatal development did not lead to phenotypic recovery.  
I. Introduction: 
TCF4 is a bHLH transcription factor that can both repress and activate transcription of 
hundreds of genes.1 bHLH proteins are involved in developmental processes, and often regulate 
proliferation, determination of cell fate, and cellular processes in terminally differentiated 
cells.1,2,3,4 TCF4, specifically, regulates critical steps of development, as well as plasticity-related 
transcriptional programs in the central nervous system.5 TCF4 also regulates glial cell 
differentiation, including the maturation of oligodendrocyte progenitor cells.6 Most crucially, 
TCF4 is critical for the normal development of the mammalian nervous system.6,7,8,9 Alterations 
to TCF4, therefore, disrupt the development of the nervous system and are linked to 
neurodevelopmental and psychiatric disorders.  
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PTHS is caused by a mutation or deletion in one copy of TCF4 that leads to its 
haploinsufficiency.10 PTHS is a rare neurodevelopmental disorder characterized by severe 
intellectual disability, developmental delay, lack of speech, distinct facial features, and 
hyperventilation.11,12,13 MRI results show anatomical changes in the brains of PTHS patients, 
including an underdeveloped corpus callosum, enlarged ventricles, thin hindbrain, and small 
hippocampus.14,15,16,17 The behavioral and anatomical phenotypes observed in PTHS patients 
indicate the importance of proper TCF4 gene expression for normal brain development and 
function.  
 TCF4 regulates the expression of hundreds of other genes, so treatment strategies 
targeting downstream molecular targets are not feasible. Treating the root cause of PTHS can 
circumvent this obstacle, so the most promising therapeutic strategy is to normalize TCF4 
expression. Previous studies of phenotypically similar neurodevelopmental disorders provide 
evidence that genetic disorders can be treated by normalizing gene expression levels. For 
example, Angelman syndrome (AS) is a neurodevelopmental disorder caused by loss of the 
maternal ubiquitin ligase UBE3A. UBE3A reinstatement rescued neurocognitive and motor 
deficits in a mouse model of AS during embryonic development.18 A similar disorder, Rett 
syndrome, is caused by loss of function of methyl CpG-binding protein 2 (MECP2). Reinstating 
MECP2 extended lifespan and ameliorated neurological deficits in mouse models of Rett 
syndrome.19,20,21 Each of these studies provides substantial evidence for the efficacy of genetic 
normalization strategies in similar genetic disorders to PTHS. In PTHS itself, Tcf4 upregulation 
has shown promise as a therapeutic solution. In PTHS, inhibition of histone deacetylase 2 
(HDAC2) ameliorated learning and memory deficits, likely due to the upregulation of Tcf4.22 
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The success of Tcf4 upregulation indicates that addressing TCF4 deficiency can lead to 
phenotypic improvements.  
Both human and mouse TCF4 expression levels are higher during embryonic and early 
postnatal development than late postnatal development, making these two developmental stages 
critical to normal TCF4 function and brain development.23,24 TCF4 expression persists at lower 
levels during adulthood, so it is currently unclear whether PTHS is caused exclusively by 
disruption of TCF4 function during brain development or whether TCF4 dysfunction in the 
mature CNS also contributes to PTHS phenotypes.25 Thus, it is imperative to determine the latest 
age by which we can normalize TCF4 expression and still rescue PTHS-associated phenotypes. 
In this study, two developmental stages were tested: embryonic and neonatal development. 
Clinical studies have also shown that PTHS phenotypes develop during the first year of life, 
further distinguishing early development as a critical stage for therapeutic intervention.26 
Accordingly, we hypothesize that both embryonic and early postnatal reinstatement of TCF4 will 
ameliorate PTHS-associated phenotypic deficits. 
 To test the hypothesis, we used a novel, conditional TCF4 mouse model in which we can 
reinstate the capacity to express full-length, functional TCF4 with temporal precision through 
Cre-Lox recombination. Embryonic reinstatement of TCF4 was achieved using a mouse model 
with widespread Cre expression during embryonic development. There is currently no transgenic 
mouse line available that allows Cre to be expressed in all cells during neonatal development, so 
we used an adeno-associated virus (AAV) to deliver a Cre gene to brain cells postnatally. In 
order to determine the optimal method for virus administration, we examined the distribution of 
TCF4 in the mouse brain, so that the ideal Cre distribution can be established. Precise knowledge 
of TCF4 expression patterns is also necessary to identify future therapeutic targets in the brain, 
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as well as options for exploring the molecular mechanisms of PTHS pathology. Using 
immunohistochemistry, we visualized the overall expression patterns of TCF4 using a GFP 
marker in Tcf4LGSL/+mice, and used in situ hybridization (ISH) to specifically quantify Tcf4 
expressing cells across different brain regions. With this detailed picture of endogenous TCF4 
expression patterns, we then were able to compare the resulting Cre distribution of two different 
viral administration routes (intravenous and intracerebroventricular) to determine which reflects 
wild type expression more closely, and found that intracerebroventricular (ICV) injection 
resulted in Cre expression similar to the biodistribution of TCF4.  
Having established methods for restoration of full-length TCF4 in both embryonic and 
neonatal mice, behavioral phenotypes were screened to determine the effects of TCF4 
restoration. An array of behavioral tests was used to compare behavioral phenotypes of each 
group to wild type. We found that the expression of Cre during embryonic development 
successfully rescues phenotypic deficits, while postnatal reinstatement of TCF4 did not improve 
PTHS-associated phenotypes. Additionally, there is evidence that delivery of viral vector had 
deleterious effects, though this mechanism is not yet clear.  
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II. Results 
Postnatal TCF4 expression patterns persist throughout development 
Tcf4LGSL/+ mice allow for both the usage of GFP as a fluorescent reporter of TCF4 
expression, and the restoration of full-length TCF4 when Cre is expressed (Figure 1A). The 
bHLH domain is involved in DNA binding, which is considered the most important functional 
domain. The insertion of a premature STOP codon prior to the bHLH domain produces TCF4 
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protein without bHLH function, which models the loss of function mutations and deletions 
responsible for PTHS. The loxP sites flanking the GFP-STOP region allow for its excision in a 
Cre-dependent manner, which results in functional wild type TCF4 production. 
We stained for GFP in Tcf4LGSL/+ mouse brains in order to visualize the biodistribution of 
TCF4 (Figure 1B). A wild type mouse brain served as a negative control, and as expected, GFP 
staining did not produce any fluorescent signals. This indicates that any fluorescence in 
Tcf4LGSL/+ mice is due to GFP insertion and not background noise or autofluorescence. We found 
that TCF4 was expressed at its highest level at P1, and over time its level diminished, but its 
spatial expression pattern persisted across development. This finding confirms previous studies 
showing that TCF4 is expressed at higher levels during neonatal development than late postnatal 
development.23,24 The cerebral cortex had prominent TCF4 expression, whereas the subcortical 
areas had relatively weak staining. More specifically, the forebrain, which includes the 
hippocampus, prefrontal cortex, and visual cortex, appeared to have the highest levels of TCF4 
expression. We found that the midbrain, which includes the thalamus and striatum, had very low 
levels of expression while the cerebellum had intermediate levels. Labeled brain regions indicate 
the important areas quantified using ISH, allowing for easy comparison of the expression 
patterns depicted by each visualization method.  
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Tcf4 mRNA expression quantitatively matches GFP expression patterns detected in 
Tcf4LGSL+/ mice 
It is possible that TCF4 expression patterns may be modified from wild type in the PTHS 
model mouse. In order to reject this possibility, we examine the distribution of Tcf4 mRNA in 
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wild type brain tissues. We performed ISH instead of immunostaining in adult wild type brain 
tissues, as commercially available TCF4 antibodies have limited success detecting low levels of 
TCF4 (data not shown), and as a result can provide misleading data.  Additionally, ISH allows 
for the examination of cell-type specific distribution, a characteristic taken advantage of in a 
parallel study. We therefore conducted ISH in adult wild type brain tissues, using a probe whose 
sequence is specific to Tcf4 mRNA, and quantified the number of cells containing Tcf4 mRNA in 
the hippocampus, prefrontal cortex, visual cortex, basolateral amygdala, striatum, and thalamus. 
We found that the hippocampus, prefrontal cortex, visual cortex, and basolateral amygdala have 
a noticeably higher proportion of Tcf4 mRNA expressing cells than the striatum and thalamus 
(Figure 2). It is apparent that the hippocampus had a higher proportion of Tcf4 mRNA expressing 
cells than the other brain regions, and the thalamus had minimal Tcf4 expression. This 
quantification result was consistent with the expression patterns observed in Tcf4LGSL+/ mice 
(Figure 1B), confirming our expectation that expression patterns are unchanged in the PTHS 




Restoring TCF4 function during embryonic development can ameliorate PTHS phenotypes 
To determine the efficacy of genetic normalization during embryonic development, we 
used several behavioral assays to measure phenotypes of Tcf4LGSL/+ mice. 
Established PTHS Mouse Model Phenotypes 
The elevated plus maze task is widely used as an index of anxiety. The time a mouse 
spends in protected arms versus in the open arms of a plus-shaped maze can indicate anxiety 
levels. An increase in closed arm time indicates increased anxiety, as anxious animals spend 
significantly more time in the closed arms of the maze.27 This assay can be used as a measure of 
deficits in the hippocampus or amygdala, as both underlie anxiety.27 
The open field task measures activity level as well as locomotion.28 An increase in 
distance traveled in the open field arena indicates hyperactivity and increased locomotion. The 
CA1 region of the hippocampus and the basolateral amygdala regulate this behavior.29 
The object location memory task is used as a measure of long-term spatial memory.30 
During the training phase, mice explore two identical objects in an open arena for 5 mins. After 
24 hours, mice explore the same objects, but one of them is placed in a new location. Mice tend 
to explore the moved object more than the unmoved object. The discrimination index is 
calculated by quantifying the preference of an animal for either object location. A positive 
discrimination index (DI) indicates preference for the relocated object, while a negative DI 
indicates preference for the unmoved object. The DI is expected to be positive in mice. 
Therefore, a decrease in the discrimination index indicates reduced hippocampus-dependent 
long-term spatial memory, since the mouse cannot remember which of the two object locations is 
familiar.30 
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Finally, the acoustic startle response test assesses sensorimotor gating.31 Sensorimotor 
gating is an important part of behavioral assessment, as it measures motor responses to sensory 
information. Additionally, motor reflex amplitude is used to show the animal’s response to a 120 
dB noise. The startle reflex is a stereotyped motor response to a sudden acoustic stimulus, that 
has been studied carefully in a variety of species.31 The reflex pathway responsible for the startle 
reflex is modulated by higher brain structures, including the hippocampus and thalamus.31,32 
These behavioral assays are chosen for our study because PTHS mice have previously 
exhibited robust phenotypes in each of these assays.33 Previous literature has measured 
phenotypic deficits in distinct mouse models of PTHS. Multiple mouse models of PTHS have 
been tested, each with a different mechanism of TCF4 disruption. For example, one model uses a 
point-mutation while another removes the bHLH domain using a Cre-LoxP recombination 
system.34 Despite these differences in mutations, each mouse model exhibited similar behavioral 
phenotypes. The model mice had an increase in the time spent in the open arm of an elevated 
plus maze, and an increase in total distance traveled in the open field task. They had a modestly 
impaired startle response, and divergent sensorimotor gating results. Using the Morris water 
maze, it was shown that PTHS model mice exhibited hippocampus-dependent spatial learning 
and memory deficits.33 These established phenotypic deficits informed us what PTHS-associated 
deficits we expect in Tcf4LGSL/+ mice.  
Behavioral testing results 
To achieve full-length TCF4 restoration during embryonic development, we crossed 
Actin-Cre transgenic mice with Tcf4LGSL/+(Tcf4LGSL/+::Actin-Cre). The Beta-Actin promoter 
drives Cre expression in every cell during embryonic development. Because Cre excises the 
LGSL insertion, Cre expression results in restored full-length TCF4. Therefore, Tcf4LGSL/+:: 
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Actin-Cre was used to determine the effects of embryonic reinstatement of wild type TCF4 on 
behavioral phenotypes. 
Phenotypic differences between wild type, Tcf4LGSL+/ , and Tcf4LGSL/+:: Actin-Cre mice 
were established using the behavioral assays previously described (Figure 3). In the elevated plus 
maze, Tcf4LGSL/+mice spent a significantly greater proportion of time in the closed arms, while 
Tcf4LGSL/+:: Actin-Cre mice spent a similar proportion of time in closed arms to wild type, and 
had a significantly reduced proportion of time in closed arm compared to Tcf4LGSL/+ (Figure 3B). 
In the open field task, Tcf4LGSL/+ mice have a significant increase in distance traveled, but 
Tcf4LGSL/+:: Actin-Cre mice travel a similar distance to wild type, and again have a significant 
reduction in distance traveled  compared to Tcf4LGSL/+(Figure 3C). The object location memory 
results show that Tcf4LGSL/+mice had a significantly decreased preference for the object moved to 
a new location, but this preference was partially restored in Tcf4LGSL/+:: Actin-Cre mice (Figure 
3D). The restoration was statistically insignificant, but the mean DI still increased. Finally, 
Tcf4LGSL/+mice have a significantly reduced acoustic startle response amplitude, while 
Tcf4LGSL/+:: Actin-Cre have a similar response to wild type (Figure 3E). The increase in motor 
response amplitude from Tcf4LGSL/+ to Tcf4LGSL/+:: Actin-Cre was significant. These results 




ICV virus injection results in high cortical Cre expression 
To test genetic normalization during neonatal development, we developed a different 
strategy. Instead of crossing with Actin-Cre transgenic mice, we used a viral vector delivery 
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strategy. We designed an adeno-associated viral vector that expresses Cre under the CAG 
promoter (AAV9/PHP.eB-CAG-Cre), which drives ubiquitous expression (Figure 4A). 
Delivering this virus to the brain results in wild type TCF4 expression. The capsid PHP.eB is 
chosen because it is a widely used gene delivery tool and is nontoxic, while AAV9/PHP.eB can 
pass through the blood brain barrier, allowing for efficient systemic delivery through the 
bloodstream.34,35,36 
There are multiple ways to deliver viral vector to the postnatal mouse brain. The two 
methods we considered are intracerebroventricular (ICV) and intravenous (IV) injection. In ICV 
injection, the virus is injected directly into the lateral ventricles of the mouse brain, whereas in 
IV injection, the virus is delivered into the temporal vein (Figure 4A). ICV injection has the 
advantage of direct delivery into the brain, but it is more invasive than IV injection. Additionally, 
IV injection may result in the most efficient transduction of the CNS.35,37 However, intravenous 
injection may result in the unintentional transduction of peripheral tissues including the heart, 
liver, and many other organs.38,39,40 
To validate transduction efficiency of each injection method, we performed the two viral 
administration routes in neonatal mice and examined Cre biodistribution three weeks after 
injection to validate transduction efficiency, as full transduction takes weeks to occur.34 Staining 
for Cre allowed us to visualize the biodistribution of Cre in mice injected with viral vector 
(Figure 4B). We observed that ICV injection produced a higher number of Cre-expressing cells 
in the cortex and hippocampus, while IV injection resulted in more widespread and diffuse 
patterns of Cre expression throughout the brain. Comparing this pattern to the TCF4 expression 
patterns in Tcf4LGSL/+ mice established previously, it is evident that ICV is preferable to IV, as 
TCF4 has intense expression in the forebrain (Figure 1B). Using ICV injection, therefore, should 
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allow for the reinstatement of full-length TCF4 in a similar biodistribution to TCF4 in wild type 
mice. Quantitatively, we see that a higher proportion of cells express Cre when ICV is used than 
when IV is used (Figure 4C). Even the lowest percentage of cells expressing Cre through ICV 
injection was twice as large as the percentage from the most effective IV injection. Overall, ICV 




Viral vector delivery results in Cre expression in both neurons and neuroglia 
We injected Tcf4LGSL/+ mice with AAV9/PHP.eB-CAG-Cre, and the biodistribution of 
Cre was assessed by immunohistochemistry. Cre enzyme is not endogenously produced in cells, 
so any Cre expression detected indicates the successful delivery of viral vector, which then 
produces Cre. We detected Cre-expressing cells throughout the brain (Figure 5A). Double 
staining for Cre and NeuN was performed in order to determine which cell types express Cre 
after viral vector delivery. NeuN exclusively marks neuronal cells. We found Cre in NeuN-
positive and negative cells, indicating that Cre is expressed both in neurons and glial cells. Only 
neuronal cells are marked by NeuN. The majority of Cre expression does occur in neurons, as 
indicated with double arrows, but there are exceptions, as indicated with single arrows. 
Additionally, the expression of Cre appeared to delete GFP expression (Figure 5B). This means 




Neonatal delivery of viral vector fails to improve PTHS Phenotypes 
Next, we tested whether reinstating TCF4 expression in neonates can rescue behavioral 
phenotypes. Our previous data showed that ICV injection produced biodistribution of Cre that 
was similar to endogenous TCF4 expression pattern in mouse brain (Figure 5). Therefore, we 
performed ICV injection of vehicle and AAV9/PHP.eB-CAG-Cre to P1 Tcf4+/+ and Tcf4LGSL/+ 
mice. We assessed behavioral phenotypes at P60 in the following groups: Tcf4+/+ injected with 
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vehicle, Tcf4+/+ injected with viral vector, Tcf4LGSL/+ injected with vehicle, and Tcf4LGSL/+ 
injected with viral vector. 
In order to discover any resulting phenotypic changes, we used the same behavioral 
assays used previously, excluding object location memory once the failure of neonatal TCF4 
reinstatement was clear. Injection of vehicle (saline solution) provided a control for the virus to 
guarantee that phenotypic differences can be attributed to genotype or presence of viral vector, 
rather than potential side effects of the injection process. Phenotypic differences between the 
four groups were established (Figure 6). Wild type mice injected with vehicle had results 
consistent with previous wild type results, showing that the injection of vehicle had no effect on 
behavior. Injection of virus, however, negatively affected behaviors. 
Statistically significant differences between groups were inconsistent across behavioral 
assays (Figure 6). In the elevated plus maze, wild type injected with virus, mutant injected with 
vehicle, and mutant injected with virus all spent significantly more time in the open arms than 
wild type injected with vehicle. In the open field task, mutant mice injected with virus traveled 
significantly farther than both  and mutant mice injected with vehicle. Finally, mutant mice 
injected with virus had a significantly reduced motor reflex amplitude compared to wild type 
mice injected with vehicle. Though no other statistically significant relationships were found, the 
trends seen provide a robust source of information. Consistently we found that wild type mice 
injected with virus had increased deficits compared to wild type mice injected with vehicle,  
while mutant mice injected with virus had increased deficits compared to mutant mice injected 
with vehicle. These comparisons indicates that the injection of virus had a deleterious effect on 




PTHS is a debilitating neurodevelopmental disorder with no known cure. It is caused by a 
mutation in the TCF4 gene, which leads to reduced TCF4 protein levels. TCF4 regulates the 
transcription of hundreds of other genes. TCF4 is also implicated in other disorders, such as 
schizophrenia and non-syndromic intellectual disability.41,42,43 Thus, our study has additional 
relevance beyond its applications for PTHS. 
In this study, we explored the feasibility of treating PTHS by normalizing TCF4 
expression. Previous studies demonstrated that TCF4 is expressed at high levels during 
embryonic and neonatal development,23,24 highlighting that proper TCF4 expression during these 
developmental stages is required for normal brain function. Therefore, we hypothesized that 
restoring TCF4 function in embryonic and neonatal development can rescue PTHS-associated 
phenotypes. Accordingly, in this study, we conditionally re-expressed wild type Tcf4 in the 
PTHS mouse model and performed behavioral assays to determine whether gene reactivation 
reversed phenotypic deficits. This study can inform future genetic normalization strategies to 
treat patients with PTHS by determining the existence of a critical window for effective 
intervention. Exploration of neonatal intervention in particular has significant clinical relevance, 
as neonatal intervention would not require prenatal diagnosis, unlike embryonic intervention. 
Pharmacological or genetic approaches to cure PTHS will require knowledge of where 
Tcf4 is active in the brain. Here, we established brain region specific expression of TCF4 by 
taking advantage of the TCF4 fluorescent reporter mouse. We additionally performed ISH to 
examine the distribution of Tcf4 mRNA in wild type brain tissues. In addition to providing 
pharmacological targets, detailed knowledge of TCF4 distribution in the brain can help explain 
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PTHS pathology. As a results, this study provides a robust source of information for future 
clinical efforts for the treatment of PTHS. 
Characterization of a conditional Tcf4 mutant and early embryonic gene reactivation 
We identified the behavioral phenotypes of Tcf4LGSL/+ mice that can be used as a baseline 
to determine the effects of Tcf4 reinstatement, and note changes from wild type in every 
behavioral assay. We found that Tcf4LGSL/+mice exhibited deficits in anxiety-like behavior 
compared to wild type mice. Because the hippocampus and amygdala are responsible for 
anxiety,27 it is possible that these brain regions are critically affected by loss of TCF4 function. 
Our finding that the hippocampus and amygdala have high levels of TCF4 expression supports 
this possibility. Tcf4LGSL/+ mice exhibited hyperactivity and increased locomotion in the open-
field arena. The increased locomotion raises the possibility that motor deficits are not responsible 
for behavioral phenotypes seen, as mice with motor dysfunction would be unlikely to travel 
farther than healthy mice. Previous work showed that exposure to the open-field arena increased 
neuronal activity in the CA1 region of the hippocampus as well as the basolateral amygdala.29 
Therefore, the results of the open field task provide additional evidence for the important role of 
TCF4 in the hippocampus and amygdala. Tcf4LGSL/+mice showed deficits in long-term spatial 
memory in the object location memory task. Long-term spatial memory relies heavily on the 
hippocampus.44 Thus, our data suggests that TCF4 likely plays an important role in hippocampal 
functions. This matches the expression patterns we established, as TCF4 was highly expressed in 
the hippocampus throughout development. Furthermore, loss of TCF4 function has been shown 
to cause reduced hippocampal volume, confirming the substantial role TCF4 plays in 
hippocampal development16. 
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Finally, Tcf4LGSL/+mice exhibited disrupted sensorimotor processing. The specific neural 
pathway that mediates this reflex consists of auditory information traveling to the cochlear 
nucleus, which projects to the reticular pontine nucleus.31 TCF4-deficient mice had disrupted 
pontine nucleus development, suggesting that TCF4 plays an important role in pontine nucleus 
development.45 Disrupted function in the pontine nucleus could accordingly cause the abnormal 
sensorimotor processing detected in Tcf4LGSL/+mice.  
Having established the presence of phenotypic deficits in Tcf4LGSL/+ mice, it was possible 
to see if these phenotypic deficits could be rescued by embryonic reactivation of Tcf4 gene 
expression. Tcf4LGSL/+:: Actin-Cre mice exhibited rescue of these behavioral abnormalities, 
confirming that embryonic reactivation of TCF4 expression is sufficient to prevent the 
manifestation of PTHS phenotypes. Thus, the window for improving autism- and anxiety-related 
phenotypes appears to be established early in embryonic development. The success of embryonic 
TCF4 restoration indicates early intervention as a promising strategy.  
There is no simple way, such as Cre-LoxP recombination, to reinstate wild type TCF4 
expression in the mutated copy of TCF4 in humans, so different strategies are necessary. Taking 
advantage of the wild type, fully functional, copy of TCF4 already present in patients with PTHS 
could be an appropriate strategy. Upregulation of the wild type copy of TCF4 in human 
embryonic development using small molecule drugs could result in enough functional TCF4 
protein to compensate for the mutated copy, ideally providing phenotypic rescue. An additional 
strategy could be a gene therapy approach. Gene therapy refers to the delivery of genetic material 
as a therapeutic intervention. The main appeal of gene therapy is its permanent curative potential, 
which makes it particularly attractive for organ systems that are hard to access using traditional 
measures, making repeated treatments burdensome.46 This includes the brain, as most drugs 
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cannot cross the blood-brain barrier. Delivery of genetic information almost always requires a 
vector, and the vector of choice for many nervous system targets is the AAV vector because of 
its safety46. Clinical trials have demonstrated the safety of AAV delivery to the CNS in over 200 
patients, making AAVs a promising choice for human PTHS treatment.47 The genetic 
information that can be delivered to the CNS via a viral vector includes transgenes encoding 
exogenous proteins, microRNAs, and antibodies.47 Gene therapy for PTHS would likely involve 
the delivery of a viral vector encoding functional TCF4. Based on the efficacy of our embryonic 
reinstatement strategy in PTHS model mice, humans with PTHS could experience phenotypic 
rescue upon embryonic reinstatement of TCF4. 
Neonatal gene reactivation 
The efficacy of neonatal intervention must also be explored, as this could be a more 
practical treatment strategy, given that prenatal diagnoses are relatively uncommon. The results 
of this study also can indicate the potential of gene therapy strategies for PTHS in humans. Cre 
expression using a viral vector (AAV9/PHP.eB-CAG-Cre) is the most promising option for 
neonatal reinstatement. To deliver this viral vector to the brain, we performed ICV injection, as it 
resulted in a high number of Cre-expressing cells throughout the cortex, where TCF4 is 
expressed at high levels. Before proceeding with behavioral assays, it was necessary to confirm 
that viral vector injection does successfully drive Cre expression, and consequently restores wild 
type TCF4. Our immunostaining results confirmed Cre expression in both neuronal and glial 
cells. Additionally, Cre-expressing cells lacked GFP expression, validating that the LGSL 
insertion was removed, and wild type TCF4 expression was reinstated. 
In wild type mice injected with virus, we expected no behavioral changes. However, 
these mice showed deficits in all behavioral assays when compared with wild type mice injected 
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with vehicle. Mice injected with vehicle showed no signs of negative effects and had comparable 
results to wild type mice tested previously, which indicates that injection procedure itself is not 
responsible for the behavioral deficits seen. There even is no significant difference between 
Tcf4LGSL/+ and Tcf4+/+ mice injected with virus, showing that the injection of virus interfered with 
the behavioral results. We are accordingly confident that the injection of virus had a deleterious 
effect on the mouse behaviors.  
Another noticeable phenotype seen in mice injected with virus was hind limb clasping. 
Limb clasping is an unusual behavior exhibited when mice are held by the tail and withdraw 
their hind legs and exhibit a bat-like posture.48 This behavior is often seen in mice with lesions in 
the central nervous system, including in the cerebellum, basal ganglia, neocortex, and spinal 
cord.48 In fact, we did observe reduced brain volume in mice treated with virus (data not shown). 
This could indicate that the injection of viral vector caused dysfunction and underdevelopment in 
the central nervous system, resulting in limb clasping behavior as well as the other phenotypic 
deficits displayed in the behavioral assays.  
There are many potential causes for the problem encountered. The viral vector encodes 
Cre under the CAG promoter, which drives high levels of gene expression. Hypothetically, only 
a single Cre enzyme is required to induce recombination and consequently restore TCF4 
function. It is possible that the high production of Cre enzyme damages brain cells.49 One 
potential experiment that could be used to elucidate the mechanism behind the increased 
impairment in mice injected with virus is to compare the amount of Cre protein present in mice 
injected with virus and Tcf4LGSL/+:: Actin-Cre mice. We know that the amount of Cre in Actin-
Cre mice is appropriate, as it successfully leads to reduced phenotypic deficits. If the amount of 
Cre expressed by viral vector is similar, we can eliminate overexpression of Cre as the cause of 
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impairment. If Cre expression is too high, then we can consider using a different promoter to 
drive lower levels of Cre expression. 
Another possibility is that the concentration of viral vector was too high, and interfered 
with brain function. Unfortunately, if the concentration of viral vector is too low, a smaller 
proportion of cells will be transduced, and TCF4 expression may not be restored in enough cells 
to result in phenotypic improvements. Already we saw that only 65% of cells were successfully 
transduced. The lack of phenotypic improvement could also be explained by insufficient 
transduction of the brain. However, this would not explain the apparent deterioration of brain 
function in wild type mice injected with virus. To determine if the concentration of viral vector 
caused impairment, we can inject Tcf4LGSL/+mice with viral vector at a lower concentration and 
determine if the same phenotypic deficits occur. If the same deficits do occur, we know that the 
concentration of viral vector was not responsible for the impairment. 
Peripheral tissues and their functions may have also been damaged. In this case, the 
phenotypic deficits seen would not have been induced by changes in brain function; instead, the 
body would be unable to properly respond to signals from the brain, resulting in the motor issues 
observed. We could characterize electrophysiological phenotypes in Tcf4LGSL/+mice injected with 
virus to determine whether behavioral impairment is caused by peripheral tissue damage. 
Previous studies showed that Tcf4 mutations in mice altered hippocampal long-term potentiation 
(LTP), a form of synaptic plasticity required for experience-dependent neurodevelopment.22,33 
Therefore, we can use LTP as a measurement of the effectiveness of neonatal Tcf4 reinstatement 
for neuronal recovery. If LTP is restored to wild type measurements in Tcf4LGSL/+ treated with 
virus, it indicates that behavioral impairments observed in the cohort treated with virus are 
potentially the result of peripheral tissue damage, rather than central nervous system impairment. 
 25 
Accordingly, this experiment will help us identify the root cause of behavioral impairment in 
mice treated with virus. Any combination of the described factors could have affected our 
results, so it is necessary to conduct these experiments to optimize the viral vector delivery 
process. With an optimized viral vector delivery process, neonatal TCF4 reinstatement can be 
explored again. 
TCF4 Distribution 
In addition to providing a standard for viral vector delivery, establishing a clear picture of 
Tcf4 expression patterns can indicate opportunities for future therapeutic intervention for 
individuals with PTHS. With detailed knowledge of TCF4 distribution, the pathology of PTHS 
can be illuminated more easily, and brain regions to target for intervention become apparent. 
Furthermore, the biodistribution of TCF4 can provide evidence for its functions in each brain 
region.  
We accordingly examined the expression patterns of TCF4 throughout brain development 
in mice. Until now the functions of TCF4 have only been carefully examined in the cortex and 
hippocampus. It has been previously shown that TCF4 regulates neuronal migration and laminar 
formation in the cortex.50 TCF4 expression has been predicted to be highest in the cortical areas, 
as a loss of function of TCF4 disrupts columnar organization in the cortex.51 Additionally, loss of 
TCF4 function results in reduced hippocampal volume and decreased cortical diameters.16,52 Our 
findings confirm the critical role of TCF4 in the hippocampus and cortex, as both have high 
expression levels of TCF4. The quantitative analysis we performed in conjunction with ISH can 
be used to make conclusions about the roles of TCF4 in each brain region. Since the 
hippocampus had high expression levels, we conclude that TCF4 plays an important role in 
memory. This hypothesis is supported by the results of our behavioral assays, as Tcf4LGSL/+ mice 
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have deficits in long term spatial memory. The high expression levels in the visual cortex imply 
that TCF4 may play a previously overlooked role in the visual cortex. This aligns with the vision 
impairment frequently seen in PTHS patients.53 The basolateral amygdala also had high 
expression levels of TCF4. The basolateral amygdala is involved in anxiety and spatial-related 
emotion.54 Our behavioral assays showed that Tcf4LGSL/+ mice had anti-anxiety behavior, as well 
as impaired spatial memory. These observations indicate that TCF4 may play a crucial role in the 
function of the basolateral amygdala. The high expression levels in the prefrontal cortex confirm 
previous findings that TCF4 plays a critical role in cortical development.  
The findings of this study enhance the available fundamental background knowledge of 
TCF4 distribution and function throughout the brain, and can help clarify PTHS pathology. 
Additionally, our results describe brain regions and structures ideal for future therapeutic 
intervention. A study that could extend upon this work would be to investigate not only brain 
regions expressing TCF4, but also specific cell types. This could further illuminate PTHS 
pathology and provide more specific cellular targets for treatment.  
Conclusion 
The success of embryonic genetic normalization and the distribution of TCF4 established 
can guide future treatment development efforts in PTHS. Treatments targeting brain regions with 
high expression levels of TCF4 during embryonic development may be a promising strategy. The 
efficacy of neonatal reinstatement is inconclusive, but we are optimistic that a modified viral 
vector delivery process will lead to improved outcomes in PTHS model mice. 
 
IV. Materials and Methods: 
Animals 
 27 
Tcf4LGSL/+ mice were generated through the University of North Carolina, Chapel Hill 
(UNC) Animal Models Core facility. We utilized CRISPR/Cas9-mediated homologous 
recombination to generate Tcf4-LoxP-GFP-Stop-LoxP (Tcf4LGSL) knock-in mice on the 
C57BL/6J background. The Tcf4LGSL allele was generated by inserting a cassette, comprised of a 
LoxP site, adenovirus splice acceptor, porcine teschovirus-1 2A (P2A) site, EGFP coding 
sequence designed to be in-frame with upstream Tcf4 codons, 3 copies of SV40 polyadenylation 
sequence (Stop), FRT site, and another LoxP site, and this cassette was inserted into Tcf4 intron 
17. The Tcf4LGSL/+ knock in mice were genotyped via PCR. The primer set of Tcf4-5ScF1 (5’-
GCACTTCAGGGATCGCTTA-3’) and AdSA-R2 (5’-
GGGACAGGATAAGTATGACATCATC-3’) was used to amplify the  or LGSL knock in 
allele.  
Tissue Preparation 
To obtain and prepare the tissues for all immunostaining steps for both GFP and other 
markers, postnatal mice were anesthetized with sodium pentobarbital (60 mg/kg) via 
intraperitoneal injection before transcranial perfusion with 25 ml of phosphate-buffered saline 
(PBS), immediately followed by phosphate-buffered 4% paraformaldehyde (pH 7.4). The brains 
were then fixed overnight at 4°C before incubation for 24 hours in PBS with 30% sucrose. The 
brain samples were then sectioned sagittally at 40 micrometers using a freezing sliding 
microtome. Sections were stored at -20°C in a cryopreservative solution (45% PBS, 30% 




For immunofluorescent staining, brain sections were rinsed several times with PBS and 
PBST (PBS with 0.2% Triton-X-100) before being blocked with 5% NGST (normal goat serum 
in PBST) for 1 hour at room temperature. Sections were incubated with primary antibodies 
(1:10,000 anti-chicken GFP, 1:1,000 anti-guinea pig NeuN, 1:1,000 and anti-mouse Cre) diluted 
in NGST at 4°C overnight. Sections were then rinsed several times with PBST and then 
incubated with secondary antibodies for 1 hour at room temperature. The following secondary 
antibodies from Invitrogen were used at a 1:1000 dilution: goat anti-guinea pig Alexa 594; goat 
anti-mouse Alexa 647; and goat anti-chicken Alexa 488. DAPI (Invitrogen D1306) was added 
during secondary antibody incubation as a nuclear counterstain. 
In Situ Hybridization 
Wild type mouse brains were extracted and immediately snap-frozen in dry ice to prevent 
the degradation of mRNA. Coronal brain sections were taken at a thickness of 16 mm using a 
cryostat, and stored at -80° Celsius. For in situ hybridization, the RNAscope Fluorescent 
Multiplex Assay, an ISH technique designed to visualize multiple cellular RNA targets in fresh 
frozen tissues, was used. The target region of the Tcf4 mRNA probe we used was 1120 to 2020 
base pairs of mouse Tcf4 mRNA. The staining procedure was completed to manufacturers’ 
specifications (ACDBio 2011), which included pretreatment of the tissues with a protease, 
followed by application of the Tcf4 mRNA probe, and three amplification steps. 
Injection 
         For intracerebroventricular (ICV) injection, 1 μl of AAV9/PHP.eB-CAG-Cre (3.0 x 1010 
vg) was injected into the lateral ventricles of P1  mice. For intravenous (IV) injection, 10 μl of 
AAV9/PHP.eB-CAG-Cre (3.0 x 1011 vg) was injected into the temporal (or facial) vein at P1. 
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Injection targeting was visualized by transillumination of the head and by the addition of 0.1% 
Fast Green dye to the virus solution. 
Imaging and Data Analysis 
Consistent images were obtained with Zeiss LSM 710 Confocal Microscope, equipped 
with ZEN imaging software (Zeiss, Jena, Germany). Identical imaging parameters were used for 
all images compared with one another. Brightness and contrast were adjusted identically using 
Fiji software.  
For immunostaining, images were taken of entire brain sections, while for ISH, images 
were taken from consistent coronal section planes across each different mouse brain. The DAPI 
image was then converted to 8-bit black and white image using Fiji, and the threshold was 
adjusted using the Huang Method, revealing the highest intensity DAPI staining. For the images 
with Tcf4 staining, the isoData threshold was instead used. To determine the expression levels of 
Tcf4, the mean intensity of Tcf4 expression for each nucleus (as shown by DAPI) was calculated 
using the CellProfiler software, and the percent of cells where Tcf4 mRNA is colocalized with 
DAPI was found.  
To analyze the viral injection procedure, the fluorescence intensity of Cre for each cell 
was determined using Fiji, and an intensity threshold was set manually to determine the percent 
of cells considered Cre-expressing. Cells with fluorescence intensity above the determined 
threshold were considered Cre-expressing.  
Behavioral Tasks 
To determine the behavioral phenotypes of each mouse group, we used the following 
behavioral tests: elevated plus maze, open field, object location memory, and acoustic startle, in 
that order. We chose this order because acoustic startle is very stressful for the mice and could 
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affect their behavior after the test. Body weight was also recorded before and after the behavioral 
tests. The mice were tested beginning at postnatal day 60 (P60), and testing ended by P100.  
Elevated Plus Maze 
The maze was designed with two open and two closed arms, each 20 cm in length, 8 cm 
in width, and the closed arms had a height of 30 cm. The center was 8  by 8 cm, and the entire 
maze was elevated 50 cm above the floor. Mice were habituated in the testing room for twenty 
minutes prior to the task. Each mouse was placed in the center of the maze and freely explored 
the maze for 5 mins. The amount of time spent in either open or closed arms was measured.. 
Videos were recorded with a Logitech camera and analyzed using Ethovision XT 15.0.  
Open Field 
Each mouse was placed into an open-field chamber (41 x 41 x 30 cm) crossed with a grid 
of photobeams for 60 minutes (VersaMax system; AccuScan Instruments). The VersaMax 310 
system tracks the movement of the mouse and measures total distance traveled. 
Object Location Memory 
Mice were habituated for three days, for five minutes each, in an empty square arena (30 
x 30 cm). On the fourth day, mice were placed into the same arena with two objects for fifteen 
minutes. This serves as the training phase, in which mice become accustomed to the objects. On 
the fifth day, the mice were tested by placing one of the objects in a new location. Ethovision XT 
15.0 (with ThorLabs camera) measures the amount of time the mouse explores each object. 
Discrimination index was calculated as follows: (time exploring a moved object - time exploring 
an unmoved object)/(total time exploring)*100. Discrimination Index (DI) is a measure of the 
mouse’s preference for the moved object, where a positive DI indicates preference for the moved 
object and negative indicates preference for the unmoved object. Mice with a training phase DI 
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of greater than 20 or less than -20 were considered to have a significant bias for one location and 
were excluded from analysis. Similarly, mice who explored the objects for less than 3 seconds 
total during training or testing were eliminated from consideration in the data analysis. 
Acoustic Startle 
 As described in Thaxton and Kloth, et al., mice were placed into small plexiglass tubes 
within larger, sound-proof chambers33 (San Diego Instruments SR-Lab system). Each cylinder 
was placed on a transducer that quantified the vibrations. Acoustic startle stimulus at 120 dB for 
40 ms occured, and the startle amplitude, detected by the vibrations, was measured. 
Behavioral Data Analysis 
 For each phenotypic measure, a one way Anova test was used to determine significant 
differences between groups, with a confidence level of 95%. For comparison of ICV and IV 
injection, an unpaired t-test was used with a confidence level of 95%. Throughout, one asterisk 
denotes p<0.05, two denote p<0.01, and three denote p<0.001. 
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